Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure
Background: Heart Failure (HF), a leading cause of morbidity and mortality, represents a relevant trigger for the development of frailty in the elderly. Inflammation has been reported to play an important role in HF and frailty pathophysiology. Galectin-3 (Gal-3), whose levels increase with aging, exerts a relevant activity in the processes of cardiac inflammation and fibrosis. The aim of the present study was to investigate the potential of Galectin-3 to serve as a biomarker of frailty in HF patients. Methods: 128 consecutive patients aged 65 and older with the diagnosis of systolic HF underwent a frailty assessment and blood sample collection for serum Gal-3 detection. A multivariable regression analysis and decision curve analysis (DCA) were used to identify significant predictors of frailty. Results: Frailty was present in 42.2% of patients. Age: Odds Ratio (OR) = 3.29; 95% Confidence Interval CI (CI) = 1.03-10.55, Cumulative Illness Rating Scale Comorbidity Index (CIRS-CI): OR = 1.85; 95% CI = 1.03-3.32, C-Reactive phase Protein (CRP) OR = 3.73; 95% CI = 1.24-11.22, N-terminal-pro-Brain Natriuretic Peptide (NT-proBNP): OR = 2.39; 95% CI = 1.21-4.72 and Gal-3: OR = 5.64; 95% CI = 1.97-16.22 resulted in being significantly and independently associated with frailty. The DCA demonstrated that the addition of Gal-3 in the prognostic model resulted in an improved clinical 'net' benefit. Conclusions: Circulating levels of Gal-3 are independently associated with frailty in elderly patients with systolic HF.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Journal of clinical medicine - 9(2020), 7 vom: 14. Juli |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Komici, Klara [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarker |
---|
Anmerkungen: |
Date Revised 28.09.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/jcm9072229 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM31250747X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM31250747X | ||
003 | DE-627 | ||
005 | 20231225144548.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/jcm9072229 |2 doi | |
028 | 5 | 2 | |a pubmed24n1041.xml |
035 | |a (DE-627)NLM31250747X | ||
035 | |a (NLM)32674344 | ||
035 | |a (PII)E2229 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Komici, Klara |e verfasserin |4 aut | |
245 | 1 | 0 | |a Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.09.2020 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Background: Heart Failure (HF), a leading cause of morbidity and mortality, represents a relevant trigger for the development of frailty in the elderly. Inflammation has been reported to play an important role in HF and frailty pathophysiology. Galectin-3 (Gal-3), whose levels increase with aging, exerts a relevant activity in the processes of cardiac inflammation and fibrosis. The aim of the present study was to investigate the potential of Galectin-3 to serve as a biomarker of frailty in HF patients. Methods: 128 consecutive patients aged 65 and older with the diagnosis of systolic HF underwent a frailty assessment and blood sample collection for serum Gal-3 detection. A multivariable regression analysis and decision curve analysis (DCA) were used to identify significant predictors of frailty. Results: Frailty was present in 42.2% of patients. Age: Odds Ratio (OR) = 3.29; 95% Confidence Interval CI (CI) = 1.03-10.55, Cumulative Illness Rating Scale Comorbidity Index (CIRS-CI): OR = 1.85; 95% CI = 1.03-3.32, C-Reactive phase Protein (CRP) OR = 3.73; 95% CI = 1.24-11.22, N-terminal-pro-Brain Natriuretic Peptide (NT-proBNP): OR = 2.39; 95% CI = 1.21-4.72 and Gal-3: OR = 5.64; 95% CI = 1.97-16.22 resulted in being significantly and independently associated with frailty. The DCA demonstrated that the addition of Gal-3 in the prognostic model resulted in an improved clinical 'net' benefit. Conclusions: Circulating levels of Gal-3 are independently associated with frailty in elderly patients with systolic HF | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a biomarker | |
650 | 4 | |a elderly | |
650 | 4 | |a frailty | |
650 | 4 | |a galactin-3 | |
650 | 4 | |a heart failure | |
700 | 1 | |a Gnemmi, Isabella |e verfasserin |4 aut | |
700 | 1 | |a Bencivenga, Leonardo |e verfasserin |4 aut | |
700 | 1 | |a Vitale, Dino Franco |e verfasserin |4 aut | |
700 | 1 | |a Rengo, Giuseppe |e verfasserin |4 aut | |
700 | 1 | |a Di Stefano, Antonino |e verfasserin |4 aut | |
700 | 1 | |a Eleuteri, Ermanno |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 9(2020), 7 vom: 14. Juli |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2020 |g number:7 |g day:14 |g month:07 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm9072229 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2020 |e 7 |b 14 |c 07 |